A novel CRISPR-Cas9 strategy to target DYSTROPHIN mutations downstream of exon 44 in patient-specific DMD iPSCs
Ontology highlight
ABSTRACT: Here, we performed CRISPR-cas9 mediated genetic correction in DMD patient derived iPSC and then differentiated them into in vitro myotubes. Pairing bulk RNA sequencing between Wild-type (WT), DMD and the corrected counterparts we were able to differentiate the molecular changes that occurs during the absence of dystrophin.
ORGANISM(S): Homo sapiens
PROVIDER: GSE262976 | GEO | 2024/05/30
REPOSITORIES: GEO
ACCESS DATA